NextPlat Corp

Good morning, ladies and gentlemen, and welcome to the next Platcorp 2025 Third Quarter Earnings Conference Call. Certain statements made during this conference call constitute forward-looking statements. These statements include the capabilities and success of the company's business and any of its product services or solutions. The words believe, forecast, project, intend, expect, plan, should, would, and similar expressions and old statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risk, uncertainties, and other factors, any of which could cause the company to not achieve some of all of its goals or the company's previously reported actual results, performance, financial, or operating, including those expressed or implied by such forward-looking statements. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The company assumes no and hereby disclaims any obligation to update the forward-looking statements made during this call. Joining us on the call today are David Phipps, Chief Executive Officer and President, Amanda Ferriero, Chief Financial Officer, and Bayrut Nurkut, Vice President of Healthcare Operations. I'll now turn over the meeting to David Phipps for his opening remarks.

Good morning, and welcome to the next GLATS third quarter 2025 earnings call.

Thank you for joining us. Our objective today is to highlight many of the changes that we've undertaken in the third quarter, many of which will be more fully realized on a sequential basis starting in the fourth quarter of 2025 and throughout fiscal year 2026. Although our results of operations for the third quarter 2025 are not what we would have liked, we believe that our efforts resulted in favorable reductions in operating expenses and cash outflows and improvement in our pharmacy and e-commerce revenue and profitability. Operationally, improvements were evident late in the third quarter and have continued into the fourth quarter, a positive trend we expect to continue. After I recap the developments in the third quarter, Berute and Nkute will discuss activities in our healthcare segment. Amanda Ferriero, our CFO, will review our financial results, and then I will provide some concluding high-level remarks on our long-term objectives and developments, which we believe will positively drive the business forward. After that, we will then conclude the conference call by responding to questions that were submitted by our shareholders. Before I start, I would like to comment on our latest leadership updates. First, I wish to thank Cecile Monick for her efforts as CFO, leading our financial team, and for her support during our transition to our new CFO, Amanda Ferriero. I also wish to welcome Boruse Mokute as Vice President of Healthcare Operations, who is joining us on this call today. Now, in terms of the business, as we discussed with you during our last earnings conference call and in our recent CEO shareholder updates, our team has been busy implementing a series of actions designed to improve operations, reduce costs and grow the business. As I stated earlier, although overall results of the third quarter do not reflect the full impact of our efforts, We did see meaningful improvements to operating metrics in September, and we believe they will be more fully clear in our results for the fourth quarter and into next year. For those of you that are new investors in our company, I'd like to review Nixplat's business model. This is built around three core segments. Healthcare services through our PharmCo RX pharmacies, communications products and services through our global Telesat, Orbital Satcom, and Outfitter satellite subsidiaries, and our e-commerce development program supporting the sales of U.S.-produced products into the Chinese market. We provided an extensive review of these segments in our recent shareholder lesson released on October the 8th. You can find this on our website. I'd like to now provide a further update on our progress since that date, most of which is reported in more detail in our quarterly interim financial report on Form 10Q, which we have just released. In our healthcare segment, we're continuing to see improvements resulting from our cost reduction efforts and additional investments in business development. To illustrate these improvements, Amanda will provide a third quarter to second quarter review of the financial results. Overall, we're realizing significant revenue and profitability improvements from our business development initiatives started in the second quarter. This is highlighted by new contracts with a state prime contract holder, and expanded business within the 340B space. Our leadership team has been successful in re-engaging with a number of important customers who have, for various reasons, produced business with us over the last few quarters. These efforts have already contributed to improved description volumes late in the third quarter and into the early part of the fourth quarter. Borutse will provide more insight into our health operations in a moment. In our e-commerce and communications segment, these are the most recent highlights. During the quarter, our e-commerce segment continued to see robust sales for satellite-based connectivity and IoT products through our various e-commerce sites, as well as high-margin recurring revenue, which continues to run at record levels. We are continuing to expand our portfolio of cutting-edge connectivity products, and we've grown our customer, consumer, and enterprise base with new and existing relationships. Recent highlights here are the selection of GTC as the exclusive distributor for personal messaging and tracking products by a leading global satellite network operator for countries in the Nordic region, and the initial sales of Starlink products in the U.S. through our Outfit for Satellite unit. Sales of Opco Healthcare branded human health and wellness products in China continue to show good sell-through despite lingering challenges of limited inventory levels. We are currently experiencing record sales volumes of Opco products during the current 11.11 event, the world's largest sales event. In September, we also launched our Florida Sunshine range of nutraceutical products in the UK and the EU, and we began processing orders via Amazon and Shopify e-commerce storefronts. Launching a new brand in new markets always takes time, and therefore initial sales are very modest as expected. but we are excited to be preparing the launch of an AI-driven marketing campaign for Florida Sunshine in partnership with an experienced healthcare brand, marketing firm, and to advancing our storefront on Alibaba's T-Mall store in China. Now we've been approved to sell in the country. I would now like to turn the call over to Barute for her update.